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Introduction 
Rheumatoid arthritis (RA) is an autoimmune disease affecting ap-
proximately 1% of  the population in the Western world character-
ized by chronic inflammation of  the joint synovium by activated 
inflammatory leukocytes (such as T-helper [Th] lymphocytes and 
monocytes), synovial hyperplasia, neo-angiogenesis, and progres-
sive destruction of  cartilage and bone [1]. The pathogenesis of  
RA is a multi-factorial process involving genetic and environmen-
tal factors that can result in systemic immunological dysfunction 
under certain conditions [2]. Specifically, inappropriate regulation 
of  CD4+ Th cells has been implicated in the pathophysiology of  
both RA and systemic lupus erythematosus (SLE) [3, 4], and sev-
eral studies have shown that RA is associated with Th1/Th17 cell 
cytokine imbalances [5, 6]. As cytokine-driven activation of  CD4+ 
Th cells is critical to the elimination of  pathogens, a chronic im-
balance in cytokine production by Th cells is likely a key factor in 
the development of  RA.
Therefore, in this work, we profiled the cytokine expression from 
three key Th cell types (Th1, Th2, and Th17) in peripheral blood 
samples from RA patients by flow cytometric bead array (CBA) in 
order to correlate the resulting cytokine expression profiles with 
RA activity.
Materials and Methods
Ethics Statement
The study protocol was approved by the Regional Committee on 
Ethics for Human Research at the Faculty of  the Second Hospital 
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Abstract
Background: Rheumatoid arthritis (RA) is the most common chronic autoimmune disease affecting multiple joints. A 
chronic imbalance in cytokine production by T-helper (Th) cells is likely a key factor in RA development. Our objective 
was to profile the serum cytokine expression from three key Th cell types (Th1, Th2, and Th17) in RA patients in order to 
correlate the resulting cytokine expression profiles with RA activity.
Material and Methods: From a population of  RA patients (n = 71) and healthy controls (n = 18), the serum concentra-
tions of  seven cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α) were analyzed by flow cytometric bead array 
(CBA).
Results: The serum concentrations of  all seven cytokines were significantly higher in RA patients than in healthy controls. 
Interestingly, the serum concentration profiles varied with the 28-joint Disease Activity Score (DAS28), a measure of  RA 
activity derived from joint indices (tender joints and swollen joints count) and the erythrocyte sedimentation rate. In the high 
RA activity group (DAS28 > 5.1), all seven cytokines were significantly elevated. In the moderate RA activity group (DAS28 
between 3.2 and 5.1), only IL-2, IL-6, IL-10, and IL-17A were significantly increased. In the low RA activity group (DAS28 
≤ 3.2), only IL-2, IL-4, and TNF-α were significantly elevated.
Conclusions: The Th cell-derived cytokine expression profile significantly changes across varying levels of  RA activity. 
Th1/Th17 cell-derived TNF-α and Th2 cell-derived IL-4 appear to play more important roles in the early stages of  RA, 
while all seven cytokines derived from Th1, Th2, and Th17 cells (IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α) are 
overtly involved in the advanced stages of  RA.
Keywords: Rheumatoid Arthritis: RA; T-helper: Th1; Th2; Th17; Cytokine; Cytometric Bead Array; CBA.
Zili Fu et al., (2015) T-Helper Cell Cytokine Expression Profiling in Rheumatoid Arthritis Patients by Flow Cytometric Bead Array Analysis. Int J Clin Ther Diagn. S2:001, 
1-5. 2
 http://scidoc.org/IJCTD.php
of  Shanxi Medical University (Taiyuan, China). Prior to participa-
tion in the study, written informed consent was obtained from all 
subjects after a full explanation of  the procedures.
Subject Recruitment & Sample Collection
The study population consisting of  71 RA patients (21 males and 
50 females aged 18-75 years, mean age: 51.20 ± 12.18 years) were 
included based on the revised classification criteria of  the Ameri-
can College of  Rheumatology [7] (Table 1). All patients were 
seen at the outpatient immunology clinic at our hospital between 
March 2009 and February 2010. Disease duration ranged from 6 
months to 13 years (mean duration: 5.24±0.77 years). RA activ-
ity was assessed by the 28-joint Disease Activity Score (DAS28), 
which is derived from joint indices (tender joints and swollen 
joints count) and the erythrocyte sedimentation rate (ESR) [7]. 
From the total study population of  71 RA patients, 14 patients 
were segregated into a low RA activity group (DAS28 ≤ 3.2), 22 
patients were segregated into a moderate RA activity group (3.2 
< DAS28 ≤ 5.1), and 35 patients were segregated into a high RA 
activity group (DAS28 > 5.1). Eighteen healthy controls (5 males 
and 13 females aged 22–54 years, mean age: 47.48±14.43) were 
also enrolled from our hospital during the same time period.
After consenting, 5.0ml of  blood was collected from each of  the 
76 RA patients and 18 healthy controls at the time of  clinical as-
sessment. Serum was separated from the specimens at 1000 rpm 
for 15 min at 20°C. After centrifugation, sera were collected and 
stored at −80°C for later analysis.
CBA Standards Preparation
Preparation of  the CBA standards was performed according to 
the kit instructions (BD CBA Cell Signaling Flex Set, Becton 
Dickinson, USA). Briefly, Standard Tubes (12 × 75 mm) were 
labeled and arranged in the following order for purposes of  se-
rial dilution: Top Standard, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 
and 1:256. Then, 20μl of  each Cell Signaling BD CBA Flex Set 
Standard was added to the Top Standard tube. The Assay Diluent 
was added into the Top Standard tube to bring the final volume 
to 1 ml. Then, 500μl of  Assay Diluent was added into each of  
the remaining tubes. Serial dilution was performed by transferring 
500 μl from the Top Standard tube to the 1:2 dilution tube, mix-
ing thoroughly, and then repeating this process for the remaining 
tubes. The Assay Diluent served as the negative control.
CBA of  Cytokine Expression
The 50μl standard dilutions (prepared above) and test samples 
were added to the appropriate tubes. Then, 50μl mixed Capture 
Beads were transferred into each assay tube. The assay tubes were 
incubated for three hours at room temperature. Then, 50μl mixed 
PE-conjugated Detection Reagent was added to each assay tube 
and then incubated at room temperature for one hour in a dark 
room. The assay samples were washed with 1.0ml Wash Buffer 
and centrifuged at 1500 rpm for 5 minutes. Then, 300μl Wash 
Buffer were transferred into each assay tube.
The assay samples were analyzed by CBA (BD FACS Calibur Flow 
Cytometer and FCAP Array™ software). Seven cytokines were 
detected: interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-6 
(IL-6), interleukin-10 (IL-10), tumor necrosis factor (TNF-α), 
interferon-γ (IFN-γ), and interleukin-17A (IL-17A) (Figure 1). 
Because each cytokine was coated with a uniquely-sized micro-
sphere, each cytokine could be easily distinguished by CBA. The 
concentration of  each cytokine was determined according to its 
fluorescence intensity (Figure 1).
Statistical Analysis
Data were analyzed using SPSS 13.0 (IBM, USA). The experi-
mental groups were compared by one-way analysis of  variance 
(ANOVA) and Tukey's method. Student’s t-test was used to com-
pare the RA and healthy control groups. P < 0.05 was considered 
statistically significant for all analysis.
Results
CBA, which discriminates between microparticles on the basis of  
size and fluorescence by flow cytometry, takes significantly less 
time than Western blotting and provides quantitative results with 
a wider dynamic range than conventional ELISA. Here, seven Th 
cell-derived cytokines in the serum of  RA patients and healthy 
controls were measured using CBA (Figure 1). As a result, the 
serum concentrations of  IL-2, IL-4, IL-6, IL-10, IL-17A, IFN-γ, 
and TNF-α were significantly higher than those of  healthy con-
trols (p < 0.001; Table 2). However, the serum concentration pro-
files of  these various cytokines significantly varied with DSA28-
based RA activity (Table 3). Specifically, in the high RA activity 
group (DAS28 > 5.1), the serum concentrations of  IL-2, IL-4, IL-
6, IL-10, IL-17A, IFN-γ, and TNF-α were significantly elevated. 
In the moderate RA activity group (DAS28 between 3.2 and 5.1), 
only the serum concentrations of  IL-2, IL-6, IL-10, and IL-17A 
were significantly increased. In the low RA activity group (DAS28 
≤ 3.2), only the serum concentrations of  IL-2, IL-4, and TNF-α 
were significantly elevated.
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Table 1. Clinical Characteristics of  Study Participants.
Group n Age (yrs) Sex ratio
(F:M)
RA duration 
(yrs)
Swollen 
joint count*
Tender joint 
count*
ESR 
(mm/h) 
All RA patients 71 51.20±12.18 2.4:1 5.24 ±0.77 7.82±1.04 11.35±2.32 66.73±8.32
• DAS28 ≤ 3.2 14 53.17±15.23 3.1:1 3.37±0.51 4.36±0.56 5.73±0.83 45.42±6.51
• 3.2 < DAS ≤ 5.1 22 55.41±13.30 2.5:1 3.93±0.56 6.57±0.60 6.57±0.92 73.95±8.93
• DAS28 > 5.1 35 55.91±15.75 2.9:1 5.71±0.98 8.79±0.29 8.79±1.29 86.38±9.12
Healthy controls 18 47.48±14.43 2.6:1 - - - -
*From a total count of  28 joints according to DAS28.
Abbreviations: RA, rheumatoid arthritis; DAS28, 28-joint Disease Activity Score; yrs, years; F:M, female:male;                                         
ESR, erythrocyte sedimentation rate.
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Discussion
Cytokines are a group of  small molecules secreted by Th cells 
(and non-immune cells as well) that play an important role in the 
pathogenesis of  RA by promoting autoimmune and long-term 
inflammatory synovitis that results in neighboring joint tissue de-
struction [8]. The different types of  Th cells secrete an array of  
cytokines at varying levels of  expression in response to multiple 
stimuli, which results in a complex network of  self-regulating in-
terrelationships [9]. Imbalances in this Th cell-cytokine network 
likely play an important role in the chronic inflammation and joint 
damage underlying RA [10].
Th1 cells primarily secrete IFN-γ, IL-2, and TNF-α. IFN-γ is a 
key macrophage activating factor that enhances their lethality and 
also stimulates NK cells [11]. IL-2 is important in the develop-
ment of  CD4+ T-memory cells and is a key factor in CD8+ T-cell 
stimulation. TNF-α, which is also secreted by mononuclear mac-
rophages and Th17 cells, enhances expression of  endothelial cell 
adhesion molecules (such as ICAM-1), promotes the adhesion of  
leukocytes to the endothelium, and enhances vascular endothelial 
permeation. TNF-α also promotes synovial cells, macrophages, 
fibroblasts, and chondrocytes to produce IL-1, IL-8, and TNF-α 
[12]. TNF-α is also produced by activated synoviocytes within the 
inflamed intimal lining layer of  the synovial tissue in RA patients. 
Moreover, TNF-α is also expressed by activated T cells follow-
ing estrogen loss and promotes bone-resorbing osteoclast (OCL) 
formation by upregulating osteoblast production of  RANKL and 
augmenting OCL precursor responses to RANKL [13]. Because 
of  TNF-α’s key role in promoting synovial inflammation and 
bone loss, anti-TNF-α therapy is now a well-established therapeu-
tic strategy for RA patients and has been shown to act synergisti-
cally with methotrexate to improve RA symptoms [14].
Th2 cells produce IL-4 and IL-10. IL-4 prompts the differentia-
tion of  Th2 cells, forming a positive feedback loop for Th2 cell 
differentiation [4]. IL-10 inhibits the proliferation of  Th1 cells 
and impairs dendritic cell function [15]. Th2 cells also restrain in-
flammatory reactions by inhibiting Th1 and antigen-present cells.
Th17 cells produce TNF-α, IL-6, and IL-17A. Along with TNF-α, 
IL-6 is also a major inflammatory mediator in RA. Although IL-6 
does not directly stimulate synovial mother cells and chondrocytes 
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Table 2. Cytokine Expression in RA Patients Compared with Healthy Controls.
Cytokine
RA patients 
(n=76)
Healthy con-
trols (n=18) Z P
M QR M QR
IL-17A 48.7 20.2 32.50 7.10 4.24 <0.001
IFN-γ 5.40 3.15 3.60 0.65 3.40 0.001
TNF-α 4.90 4.30 3.50 0.75 3.73 <0.001
IL-10 7.10 3.40 5.10 2.25 4.02 <0.001
IL-6 15.8 42.05 6.80 3.20 4.25 <0.001
IL-4 14.6 5.00 10.90 1.95 4.31 <0.001
IL-2 14.4 4.60 11.10 1.40 4.71 <0.001
Abbreviations: RA, rheumatoid arthritis; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; M, median; QR, quartile range
Figure 1. Flow Cytometric Bead Array (CBA) Cytokine Expression Profiling by RA Activity.
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Each horizontal red strip represents one of  the seven cytokines (from top to bottom): IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-
17A. Cytokine concentration levels are plotted along the x-axis. Cytokine expression profiling was analyzed by RA activity as follows: 
(A) Healthy control group, (B) low RA activity group (DAS28 ≤ 3.2), (C) moderate RA activity group (DAS28 between 3.2 and 5.1), 
and (D) high RA activity group (DAS28 > 5.1).
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to produce PGE2 and collagenase, it does enhance the effects of  
TNF-α and IL-1 as well as affecting IL-1, IL-2, and TNF-α pro-
duction [16]. IL-17A induces inflammation and neutrophil activa-
tion and has been found to induce bone and cartilage destruction 
in RA patients [17, 18].
In the current study, serum concentrations of  IL-2, IL-4, IL-6, 
IL-10, IL-17A, IFN-γ, and TNF-α were determined to be signifi-
cantly higher in RA patients relative to healthy controls (Table 2). 
As these particular cytokines as primarily secreted by Th1, Th2, 
and Th17 cells, this study suggests that these Th cells actively 
participate the pathogenesis of  RA. This conclusion is consistent 
with that of  our previous study [19]. Moreover, we also profiled 
the expression of  these seven cytokines by RA activity. In RA 
patients with high DAS28 scores, all seven cytokines were signifi-
cantly higher as compared to healthy controls (Table 3). However, 
in RA patients with moderate DAS28 scores, the serum concen-
trations of  IL-2, IL-6, IL-10, and IL-17A were significantly ele-
vated, but those of  IL-4, IFN-γ, and TNF-α were not significantly 
elevated, compared to healthy controls. Moreover, in RA patients 
with low DAS28 scores, the serum concentrations of  IL-2, IL-4, 
and TNF-α were significantly elevated, but those of  IL-6, IL-10 
and IL-17A were not significantly elevated, compared to healthy 
controls.
Therefore, this study reveals that these seven cytokines are dif-
ferentially expressed during according to varying levels of  RA 
activity. For example, Th1 cell-derived IL-2 derived was consist-
ently and significantly increased across all levels of  RA activity. 
In contrast, IL-4 and TNF-α were significantly elevated in the 
low RA activity group but not in the moderate RA activity group. 
Based on these findings and our current understanding of  RA, 
Th1, Th2, and Th17 cells appear to play different but collabo-
rative roles during the development of  RA [15]. Th1 and Th17 
cells appear to trigger early-phase inflammation through TNF-α 
secretion, and then Th17 cells appear to further aggravate in-
flammation in the sustained phase of  RA through secretion of  
IL-17A and IL-6. Finally, Th1 cells appear to promote late-phase 
inflammation through IFN-γ and IL-2 secretion. Consistent with 
this viewpoint, a previous study on experimental autoimmune 
encephalomyelitis (EAE) mice – an animal model of  multiple 
sclerosis (MS) -- showed that absence of  the transcription fac-
tor T-bet (which is essential for the development of  Th1 cells) 
protected mice from EAE [20] Similar to RA, EAE and MS are 
autoimmune disease states mediated by CD4+ cells in which Th1 
cells play an important role, suggesting that Th1 cells play patho-
genic roles in all these autoimmune conditions. Another study on 
EAE mice found that the expression of  Th17-derived cytokines 
occurred earlier than that of  Th2 cell-derived cytokines and that 
Th2 cell-derived IFN-γ expression remained elevated long after 
Th-17 cell-derived IL-17A expression had subsided [21].
Moreover, Th2 cells appear to switch from IL-4 to IL-10 produc-
tion as RA progresses. Accordingly, synovial fluid samples from 
patients with very early RA possess elevated IL-4 levels, whereas 
synovial fluid samples from patients with established RA lacks IL-
4. Moreover, IL-4 inhibits OCL formation through prompting os-
teoblasts to produce osteoprotegerin [22, 23], and local IL-4 over-
expression has been shown to forestall joint damage and bone 
erosion while suppressing messenger RNA levels of  IL-17, IL-12, 
and cathepsin K as well as promoting IL-6 and IL-12 protein pro-
duction in a collagen arthritis mouse model; moreover, IL-4 has 
been shown to suppress Type I collagen breakdown and promote 
type I procollagen synthesis in bone samples of  arthritis patients 
in vitro [24]. As IL-4 displays a protective effect on the synovium 
and bone, these combined findings suggest that Th2 cells switch-
ing from IL-4 to IL-10 production may be a contributing factor in 
the development of  more severe forms of  RA.
Conclusion
This study reveals that the Th cell-derived cytokine expression 
profile significantly changes across varying levels of  RA activity. 
Th1/Th17 cell-derived TNF-α and Th2 cell-derived IL-4 appear 
to play more important roles in the early stages of  RA, while all 
seven cytokines derived from Th1, Th2, and Th17 cells (IL-2, IL-
4, IL-6, IL-10, IL-17A, IFN-γ, and TNF-α) are overtly involved in 
the advanced stages of  RA. Larger-scale, multicenter studies per-
forming CBA-based cytokine expression profiling on more de-
mographically heterogeneous RA patient populations (including 
subgroups for environmental confounders of  cytokine expres-
sion such as smoking status and elevated BMI levels) are needed 
to validate these promising findings.
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Table 3. Analysis of  Cytokine Expression by RA Activity†.
Cytokine
Low RA activity 
(n=14)
Moderate RA 
activity (n=22)
High RA activity
(n=35)
Healthy controls
(n=18) H P
M QR M QR M QR M QR
IL-17A 36.4 17.8 44.00* 12.70 51.35* 23.13 32.5 7.10 19.64 <0.001
IFN-γ 3.30 0.40 4.65 2.23 5.65* 3.70 3.60 0.65 16.40 0.001
TNF-α 4.80* 2.90 4.10 3.08 4.85* 5.63 3.50 0.75 16.64 0.001
IL-10 5.90 2.00 6.75* 4.28 7.40* 4.30 5.10 2.25 17.85 <0.001
IL-6 9.50 53.50 29.70* 57.40 12.75* 43.38 6.80 3.20 27.79 <0.001
IL-4 13.10* 2.00 13.80 6.93 14.75* 4.80 10.90 1.95 20.28 <0.001
IL-2 12.50* 2.50 13.00* 4.60 14.30* 5.08 11.10 1.40 23.80 <0.001
†Low RA activity, DAS28≤3.2; moderate RA activity, DAS28 between 3.2 and 5.1; and high RA activity, DAS28>5.1
*Significant difference with healthy controls (p < 0.05). 
Abbreviations: DAS28, 28-joint Disease Activity Score; RA, rheumatoid arthritis; IL, interleukin; IFN, interferon; TNF, tumor necrosis 
factor; M, median; QR, quartile range.
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